-
Listing
Strengthening Europe’s strategic autonomy through capital marketsCzechoslovak Group lists on EuronextLes merWorld’s largest defence IPO ever recorded.
Learn more about Euronext’s initiatives to enhance financing and visibility for European aerospace and defence companies -
Trading
Where European Government Bonds meet the futureFixed Income derivativesLes merTrade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo ClearingLes merEuronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLes merEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Les merThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLes merThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Les merShaping capital markets for future generations
Curetis listing anniversary
Curetis celebrates one year listed anniversary
Curetis (ticker symbol: CURE) celebrates its one-year listed anniversary at Euronext by sounding the gong. Oliver Schacht, CEO Curetis, visits Beursplein 5 and sounds the gong.
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases.
Curetis is a molecular diagnostics company focusing on the detection of severe infectious disease in hospitalized patients. Its CE IVD marked Unyvero platform is marketed across Europe and has recently also successfully completed a US FDA trial for its LRT lower respiratory tract infection cartridge.
For more information: www.curetis.com